Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
MWN-AI** Summary
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biotechnology company based in Berkeley Heights, N.J., announced its successful uplisting from the Nasdaq Capital Market to the prestigious Nasdaq Global Select Market as of March 3, 2026. This transfer is a significant milestone for Tonix, showcasing its compliance with the Global Select Market's stringent financial and corporate governance standards. The transition aims to enhance the company’s visibility to institutional investors, subsequently improving liquidity and market recognition.
Dr. Seth Lederman, the CEO of Tonix, expressed enthusiasm regarding the uplisting, highlighting it as a pivotal step towards enhancing the company’s ability to drive growth and shareholder value. The Nasdaq Global Select Market is recognized as the highest tier among the three Nasdaq market levels, offering companies that meet its rigorous criteria increased trading volumes and improved access to institutional investors.
Tonix Pharmaceuticals specializes in central nervous system (CNS) and immunology treatments, addressing areas with significant unmet medical needs. Its flagship product, TONMYA™, marks the first new fibromyalgia treatment in over 15 years. The company’s portfolio includes acute migraine medications and ongoing clinical trials aimed at evaluating the efficacy of TONMYA in treating major depressive disorder and acute stress disorder. Additionally, the firm is advancing several immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a CD40 ligand inhibitor intended to prevent kidney transplant rejection.
Overall, the uplisting to the Nasdaq Global Select Market reflects Tonix’s commitment to growth and operational excellence, and it positions the company to leverage enhanced opportunities in the biotechnology sector.
MWN-AI** Analysis
Tonix Pharmaceuticals’ recent uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market (GSM) is a notable event that investors should assess in the context of its growth trajectory and market opportunities. This elevation signifies compliance with higher financial and governance standards, potentially attracting institutional investors, enhancing liquidity, and improving visibility.
Tonix operates in the biotechnology sector, focusing on solutions for central nervous system (CNS) disorders and immunology, key areas with significant unmet medical need. Their flagship product, TONMYA™, has positioned them favorably in the competitive landscape of fibromyalgia treatments, which could bolster revenue significantly given the lack of new therapies in the market for over a decade. Furthermore, their exploration of TONMYA in treating other conditions such as major depressive disorder could diversify revenue streams and mitigate risks associated with product dependency.
The uplisting is not merely ceremonial; it typically fosters increased trading volumes and enhances a stock's credibility among investors. The Nasdaq GSM's reputation may correlate with more robust shareholder confidence, potentially driving up the stock price in the medium to long term. Moreover, the diversity of Tonix's pipeline, particularly in rare diseases like Prader-Willi syndrome, showcases their innovation and commitment to addressing niche medical markets, which could attract additional funding and partnerships.
However, investors should exercise caution. Despite the optimism surrounding the uplisting, Biotech investments can be volatile, often contingent upon clinical trial outcomes and regulatory approvals. The ongoing Phase 2 trials and development of additional candidates, such as TNX-4800 and TNX-1500, are critical junctures for the company's valuation. Hence, potential stakeholders should monitor trial results and market responses closely.
In conclusion, investors should view Tonix Pharmaceuticals as a compelling opportunity, tempered with awareness of inherent sector risks. The uplisting marks a pivotal step that may unlock growth, but ongoing performance and clinical developments will be crucial determinants for future stock performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the Company’s existing ticker symbol “TNXP.”
The uplisting to the Nasdaq Global Select Market reflects the Company’s compliance with the Nasdaq Global Select Market’s higher financial and corporate governance standards. The transition to this higher tier of the Nasdaq market may enhance the Company’s visibility among institutional investors, improve liquidity and broaden market recognition.
“Uplisting to the Nasdaq Global Select Market is an important milestone for Tonix,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We look forward to leveraging this enhanced platform to drive growth and create value for our shareholders. We're grateful for the support that has brought us here and excited about what's ahead.”
The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers and is designed for companies that meet higher financial, liquidity and corporate governance requirements than those of the Nasdaq Capital Market and the Nasdaq Global Market. The Company believes that trading on this tier will further enhance its reputation with customers, partners and investors. Companies at this level may experience increased trading volumes and greater access to institutional investors. Meeting the Global Select Market’s higher financial and corporate governance standards may also signal to the market that a company has achieved financial and operational growth.
Tonix Pharmaceuticals Holding Corp.*
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599
Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com
Media Contacts
Ray Jordan
Putnam Insights
ray@putnaminsights.com
FAQ**
How might the uplisting of Tonix Pharmaceuticals Holding Corp. (TNXP) to the Nasdaq Global Select Market impact the trading volume and visibility of the company among institutional investors?
What specific financial and corporate governance standards did Tonix Pharmaceuticals Holding Corp. (TNXP) meet to qualify for the Nasdaq Global Select Market?
Can the management of Tonix Pharmaceuticals Holding Corp. (TNXP) elaborate on how they plan to leverage their enhanced platform for growth following this uplisting?
How does the approval of TONMYA™ by Tonix Pharmaceuticals Holding Corp. (TNXP) influence its market position in CNS treatments compared to competitors?
**MWN-AI FAQ is based on asking OpenAI questions about Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).
NASDAQ: TNXP
TNXP Trading
3.18% G/L:
$13.795 Last:
116,611 Volume:
$13.28 Open:
